BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-119@catalystbrief.girapphe.com
DTSTAMP:20261117T181554Z
LAST-MODIFIED:20261117T181554Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Novartis Pharmaceuticals — everolimus [Feb 2027]
DESCRIPTION:Phase 3 primary completion: Roll-over Study to Collect and Asse
 ss Long-term Safety of Everolimus in Patients With TSC and Refractory Seiz
 ures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benef
 itting From Continued Treatment.\nSource: https://clinicaltrials.gov/study
 /NCT02962414\nhttps://catalystbrief.girapphe.com/e/119?lang=en\nNot invest
 ment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/119?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
